The bevacizumab-resistant models were indicated by no significant differences in tumor growth ratio, Ki67 or PCNA proliferative index, and microvessel density (MVD) between vehicle- and bevacizumab-treated groups (Supplemental Figure 1, A–D; supplemental material available online with this article; https://doi.org/10.1172/JCI157399DS1). This evidence concerns the gene PCNA and neoplasm.